Indivior sales drop 9% on higher rebates; India's Alkem Labs plots $210M IPO;

@FiercePharma: ICYMI yesterday: FDA cites Pfizer for shortfalls at Chinese manufacturing plant. Article | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Express Scripts looks into pharmacies at AbbVie, Teva in wake of Valeant's Philidor saga. Article | Follow @CarlyHFierce

> The Reckitt Benckiser pharma spinoff Indivior saw sales decline 9% for the first nine months of 2015, to $766 million from $844 million last year; the company cited lower market share and higher rebates as causes. Release

> The Indian drugmaker Alkem Laboratories is planning an initial public offering worth about $210 million, hoping to launch it next month. Report

> Merck KGaA's extended-release form of Glucophage won a new approval for diabetes patients with moderate kidney insufficiency and chronic heart failure. Release

Medical Device News

@FierceMedDev: ICYMI: Drug-device combo from Wyss takes a new approach on treating stroke. FierceBiotechResearch story | Follow @FierceMedDev

@EmilyWFierce: Flowonix teams with Connecticut provider for implant of drug delivery infusion pump. Article | Follow @EmilyWFierce

> Neuromodulator and artificial kidney to be reviewed under FDA's Expedited Access Pathway. More

> Fractyl gains traction with balloon ablation device for Type 2 diabetes. Article

Biotech News

@FierceBiotech: ICYMI yesterday: Merck KGaA inks cancer metabolism drug discovery alliance with Selvita. Article | Follow @FierceBiotech

@JohnCFierce: Gates, Hopp back $110M megaround for CureVac's mRNA work. News | Follow @JohnCFierce

@DamianFierce: Wait can we reconvene Grantland just to deal with this image? More | Follow @DamianFierce

> Sanofi inks a $1.5B deal to join BioNTech's growing list of oncology partners. Story

> GSK forms Keytruda combo trial pact as it plots path to 20 filings by 2020. Article

Drug Delivery News

> Amgen's Imlygic becomes first re-engineered virus to earn FDA approval as a cancer fighter. Item

> Pfizer's sickle cell anemia candidate enters trials, to the delight of delivery partner Halozyme. Story

> Imaging nanoparticle puts the heat to ovarian cancer cells. Article

> Investigational drug enables faster absorption of bioresorbable drug-eluting stents. Report

> Novartis' inhaler for COPD gets FDA approval. More

Pharma Manufacturing News

> Bain-backed compounding upstart adds second Texas manufacturing facility. Item

> Struggling Daiichi again stumbles with vaccine production. More

> First prefab biologics plant goes up in China, in 11 days. Report

> Roche completes Shanghai plant expansion, starts on new project. Story

> FDA uncovers issues at Pfizer China plant after banning products from its JV partner. Article

Pharma Asia News

> China State Council briefing outlines multilevel system for medical treatment. More

> MabSpace gets $15M as Lilly Asian Ventures bets on immune approach. Story

> China's WuXi PharmaTech, Gilead focus on analytical testing in wider partnership. Article

> HK-based Chi-Med wraps up PhI healthy volunteer trial of HMPL 523. More

> China's Biomab Holding, India's Cipla go separate ways on biosimilars. Report

And Finally... GlaxoSmithKline's ($GSK) HIV-focused joint venture ViiV Healthcare said two new injectable HIV-fighters met their 32-week goals in a Phase IIb study, with details to be unveiled at a future scientific meeting. Release

Suggested Articles

Download our solutions overview to discover how CoverMyMeds can make a difference for your brand.

In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.